Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

18 Jan 2010

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease.

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has submitted an investigational new drug (IND) amendment to the United States Food and Drug Administration (FDA) which includes the design of a proposed Phase 3 clinical trial of Neoprobe’s RIGScan® CR radiopharmaceutical.

12 Jan 2010

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

YM BioSciences Inc. today announced results of a collaboration with researchers at the University of Toronto for the development of highly potent antibody-radionuclide conjugates for use in the treatment of cancer. The approach has successfully concluded its first series of proof-of-principle experiments establishing promise for future development and application.

12 Jan 2010

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

11 Jan 2010

LFB completes conversion of all acquired preferred stock

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire Français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has converted the convertible preferred stock it previously purchased in November 2009 under the terms described in the financing agreements approved by GTC shareholders in July 2009 into a total of 5.3 million shares of common stock.

9 Jan 2010

Genentech's ACTEMRA approved to treat RA

Genentech, Inc., a wholly owned member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved ACTEMRA® (tocilizumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

8 Jan 2010

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company specializing in the development and GMP manufacture of monoclonal antibodies, fusion proteins and other therapeutic protein products, and Iconic Therapeutics, a company focused on the development of treatments for wet adult macular degeneration (wet AMD) and other ophthalmic diseases, today announced the completion of the manufacture of the first GMP lot of hI-con1(TM) recombinant Fc-Factor VII fusion protein.

8 Jan 2010

ZymoGenetics announces pricing of public offering of 14,000,000 shares

ZymoGenetics, Inc. today announced that it has priced an underwritten public offering of 14,000,000 shares of its common stock at a price of $6.00 per share. Net proceeds, after estimated underwriting discounts and commissions and estimated expenses, will be approximately $79,000,000.

8 Jan 2010

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

8 Jan 2010

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

The University of Maryland Biotechnology Institute (UMBI) today announced the exclusive licensing of a fully human antibody technology platform to Prolias, a biotechnology company working to discover and develop novel therapeutic proteins and antibodies for treatment of disease.

7 Jan 2010

MabCure signs clinical research agreement to diagnose ovarian cancer

MabCure, N.V. (“MabCure”) a wholly-owned subsidiary of MabCure Inc., a biotech company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has signed a clinical research agreement with the Ramathibodi Hospital, Mahidol University in Bangkok, Thailand.

7 Jan 2010

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

PharmAthene, Inc. a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, today commented on a Special Notice published by the US Department of Health and Human Services (DHHS), Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA) on December 29, 2009.

6 Jan 2010

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

OncoMed Pharmaceuticals, Inc. and Fluidigm Corporation today announced a new initiative to apply Fluidigm's unique microfluidic tools to the analysis of tumor cell heterogeneity, including cancer stem cells.

6 Jan 2010

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

CANCER RESEARCH UK and Cancer Research Technology (CRT), the charity's development and commercialisation arm, are to undertake a phase I clinical trial of an investigational monoclonal antibody1 drug from Merck KGaA, Darmstadt, Germany, called DI-B4 - it is announced today (Monday).

6 Jan 2010

Significant opportunity for alternative ulcerative colitis biological therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a biological therapy with a mechanism of action other than tumor necrosis factor alpha (TNF-alpha) inhibition for the treatment of moderate to severe ulcerative colitis, would earn a 25 percent patient share according to surveyed U.S. gastroenterologists. Similarly, in Europe, such an agent would also earn 25 percent patient share according to surveyed European gastroenterologists.

5 Jan 2010

Elusys Therapeutics signs contract to complete the final development of Anthim

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company, announced today that it has signed a contract potentially totaling up to $143 million to complete the final development, commercial manufacturing and licensure of Anthim, the company's late stage anthrax therapeutic.

5 Jan 2010

Monoclonal Antibody News and Research

Further Reading

Kenta Biotech and Rentschler Biotechnologie sign agreement to develop antibody against MRSA

TTI enters into definitive license agreement with Biogen Idec

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Pfizer/Medivation's AD drug Dimebon may garner peak year sales of $1.5 billion

Millipore introduces new Viresolve Pro+ Solution

Neoprobe submits IND amendment to FDA for RIGScan CR radiopharmaceutical

YM BioSciences announces results of cancer antibody-radionuclide conjugate development collaboration

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

LFB completes conversion of all acquired preferred stock

Genentech's ACTEMRA approved to treat RA

Laureate Pharma and Iconic Therapeutics complete manufacturing hI-con1 recombinant Fc-Factor VII fusion protein

ZymoGenetics announces pricing of public offering of 14,000,000 shares

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

UMBI announces exclusive licensing of fully human antibody technology platform to Prolias

MabCure signs clinical research agreement to diagnose ovarian cancer

Special Notice announces BARDA's intentions to negotiate contract modification with PharmAthene

OncoMed Pharmaceuticals and Fluidigm announce new initiative to analyze tumor cell heterogeneity

Cancer Research UK and CRT to undertake phase I clinical trial of DI-B4

Significant opportunity for alternative ulcerative colitis biological therapy

Elusys Therapeutics signs contract to complete the final development of Anthim

Immunology eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®